Company intelligence / Profile preview

WhiteSwell

Ownership: Private
Development stage: Phase 1

Overview

WhiteSwell has developed the eLym System, a novel device designed to support lymphatic drainage during treatment of acute decompensated heart failure. In early feasibility studies (DELTA-HF trial), patients treated with the eLym System showed significant reduction in tissue congestion and stable renal function. At 90 days post-treatment, only 9.5% of patients were rehospitalized for heart failure with no deaths reported—substantially better than standard-of-care diuretics alone. Six-month follow-up data also indicated reduced tissue congestion and fewer rehospitalizations compared to historical controls

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

eLym System

Phase 1

Indications: Acute decompensated heart failure

Beyond the preview

Go deeper on WhiteSwell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WhiteSwell.

Explore the full profile